Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Sundar Jagannath, MD, director, Multiple Myeloma Program, Tisch Cancer Institute at Mount Sinai Hospital, discusses the role of stem-cell transplant in the management of multiple myeloma.
Raffaele Califano, MD, consultant in medical oncology, The Christie Clinic, University Hospital of South Manchester, discusses the recent investigations into the use of immune checkpoint blockades in small cell lung cancer.
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer
To determine the frequency and clinical characteristics of parotid gland metastasis from nasopharyngeal cancer and oropharyngeal cancer and define criteria for elective inclusion of parotidean nodes in the radiotherapy clinical target volume.
The Role of Immunotherapy and Oncolytic Viruses in the Future of Cancer Treatment
Immunotherapy may not phase out surgery and chemotherapy as standards of care in cancer, but oncolytic viruses may usher in a new age of treatment.
Recent Advances Pave the Way for Exciting Future in Neuroendocrine Tumor Field
It's been an exciting year thus far for patients with neuroendocrine tumors, with the FDA approving a new treatment regimen and more advancements on the horizon.
Phase I Trial Results Demonstrate Safe Administration of Niraparib/Bevacizumab Combo in Relapsed Ovarian Cancer
Results of a phase I trial demonstrate that the combination of niraparib and bevacizumab can be safely administered to patients with platinum-sensitive relapsed ovarian cancer.
View More >


Pembrolizumab Approved by FDA for Recurrent HNSCC
Pembrolizumab Approved by FDA for Recurrent HNSCC
The FDA has approved the PD-1 inhibitor pembrolizumab as a second-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma for those who have progression on a platinum chemotherapy.
Understanding the Future of Immunotherapy in Melanoma
While there have been many recent advances in the field of melanoma regarding immunotherapy, there is still much more to come, says Antoni Ribas, MD, PhD.
Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL
With nearly a dozen new PI3K and BTK inhibitors currently in development, it is challenging to know which therapies are truly "next-generation" agents and which are "me too" products.
Shortcomings in SIRFLOX Design May Have Skewed PFS Findings
Shortcomings in the SIRFLOX study may have confounded the main findings, as the trial seemed plagued by a large number of confounding factors and a shifting trial design.
Novel Agent BION-1301 May Block Multiple Myeloma Cell Proliferation
BION-1301 may block multiple myeloma cell proliferation and reduce drug resistance and immunosuppression in the tumor microenvironment.